Silver Book Fact

The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.

Rein D, Wittenborn J, Zhang X, Honeycutt A, et al. Forecasting Age-Related Macular Degeneration Through the Year 2050. JAMA Ophthalmol. 2009; 127(4): 533-40. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/422785

Reference

Title
Forecasting Age-Related Macular Degeneration Through the Year 2050
Publication
JAMA Ophthalmol
Publication Date
2009
Authors
Rein D, Wittenborn J, Zhang X, Honeycutt A, et al
Volume & Issue
Volume 127, Issue 4
Pages
533-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about…  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Laser treatment and vitrectomy reduce the risk of blindness in patients with severe diabetic retinopathy by 90%.  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.